Original Research
Original Research
Mental Health Impact of COVID-19 Pandemic on the Mental Health of Middle-Aged and Older Adults: A Cross-sectional, Comparative Study
September 11, 2025
Older adults were found to have less depression and anxiety compared to middle-aged adults; loneliness and perception of knowledge about COVID can affect the association between the presence of...
Original Research
Validity of an Online ADHD Assessment in a Real-World Sample of Adults Seeking Web-Based Mental Healthcare
September 8, 2025
The online assessment correctly identified over 80% of ADHD-positive cases. Compared with the clinical interview, the online assessment was more conservative in rendering ADHD-positive diagnoses.
Original Research
Effects of the October 7, 2023, Terrorist Attack on PTSD, Depression, Anxiety, and Suicidal Ideation Across Distinct Exposure Groups
September 3, 2025
Prevalence and severity of psychiatric symptoms declined between 1 month and 1 year following the attack; exposure group moderated these changes. Reserve-duty combatants had the highest rates of probable...
Original Research
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
September 3, 2025
Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
Original Research
Five-Year Outcomes of First Suicide Attempts: Lethality, Recurrence, and Mortality
September 1, 2025
Recurrence of suicide attempt occurred in 37.2% of patients, with 27.8% having ≥3 attempts. Alcohol use predicted high-lethality first attempts, and female sex predicted multiple reattempts.
Original Research
Artificial Intelligence in Depression – Medication Enhancement (AID-ME): A Cluster Randomized Trial of a Clinical Decision Support System for Personalized Depression Treatment Selection and Management
August 27, 2025
This study provides preliminary evidence that longitudinal use of an AI-enabled clinical decision support system can improve outcomes in MDD.
Original Research
N-acetylcysteine for Co-occurring PTSD and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial
August 27, 2025
Among individuals with PTSD and alcohol use disorder receiving CBT and either NAC or placebo, both groups had significant reductions in both PTSD symptom severity and alcohol use, with...
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
Original Research
Levomilnacipran, but Not Duloxetine, Inhibits Serotonin and Norepinephrine Reuptake Throughout Its Therapeutic Range
August 25, 2025
Levomilnacipran and duloxetine are both potent serotonin reuptake inhibitors at all therapeutic regimens for MDD. Potent norepinephrine reuptake inhibition can be achieved from initiation with levomilnacipran, in contrast to...
Original Research
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
August 11, 2025
Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
Original Research
The Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
August 11, 2025
Medical Expenditure Panel Survey data showed that over half of adults with schizophrenia report cognitive impairments, which were associated with higher healthcare costs and lower quality of life.
Original Research
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
Original Research
Effects of Alcohol Use on Cognition in Individuals With Neurocognitive Disorders
August 6, 2025
In a memory clinic cohort of patients with neurocognitive disorders, alcohol related cognitive impairment resulted in specific deficits involving cognitive control during delayed recall task.
Original Research
Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression
July 30, 2025
The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.
Original Research
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
July 30, 2025
Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
Original Research
Klotho and Matrix Metalloproteinase-9 Levels and Their Association with Inhibitory Dyscontrol in Adolescents with First-Episode Major Affective Disorders
July 16, 2025
Adolescents with bipolar disorder and those with MDD had significantly lower Klotho levels compared with the control group; those with bipolar disorder had the highest MMP-9 levels, followed by...
